Description du projet
De nouveaux médicaments capables d’atteindre le cerveau
Le traitement des maladies neurologiques et neurodégénératives comme la maladie d’Alzheimer nécessite des médicaments capables d’atteindre le cerveau. À ce jour, la barrière hémato-encéphalique représente toutefois un obstacle important pour la plupart des traitements. Financé par le programme Actions Marie Skłodowska-Curie, le projet NeuroFerro se concentrera sur le développement de composés capables de traverser la barrière hémato-encéphalique et d’inhiber la ferroptose dans les neurones atteints. La ferroptose est un type de mort cellulaire caractérisé par une peroxydation lipidique dépendante du fer. Dans le cerveau, la peroxydation lipidique est liée à la physiopathologie de la neurodégénérescence. L’amélioration de la pharmacocinétique des inhibiteurs du projet NeuroFerro offrira de nouvelles options de traitement aux patients souffrant de troubles neurologiques ou neurodégénératifs.
Objectif
FERROptosis inhibitors for NEUROdegenerative disorders (NeuroFerro) will focus on the development of potent compounds with improved pharmacokinetic properties, including blood-brain barrier (BBB) permeability for future application in the treatment of neurodegenerative disorders. Ferroptosis is non-apoptotic programmed cell death that has been linked to the pathophysiological processes of many diseases, including dementia, Huntington’s disease, Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (ALS). Neurological disorders are one of the most significant causes of disability-adjusted life-years and death worldwide with very limited treatment available. Although ferroptosis inhibitors developed by Augustyns and Vanden Berghe (supervisors) are currently best in class compounds, they suffer from no or minor BBB permeability. Therefore the main aim of the project will be the design and synthesis of novel ferroptosis inhibitors with improved pharmacokinetic parameters and high blood-brain barrier permeability to target ferroptosis in neurodegenerative disorders.
Champ scientifique
- medical and health sciencesbasic medicineneurologydementiaalzheimer
- medical and health sciencesbasic medicinemedicinal chemistry
- medical and health sciencesbasic medicinepharmacology and pharmacypharmacokinetics
- medical and health sciencesbasic medicineneurologyparkinson
- medical and health sciencesbasic medicineneurologyamyotrophic lateral sclerosis
Mots‑clés
Programme(s)
- HORIZON.1.2 - Marie Skłodowska-Curie Actions (MSCA) Main Programme
Régime de financement
MSCA-PF - MSCA-PFCoordinateur
2000 Antwerpen
Belgique